All In MedTech

Device Trial Radar · NCT05893797

A Study of LY8888AX in Participants Using a Connected Insulin Management Platform

Assessment of Participant Adherence and Glucose Control While Using a Connected Insulin Management Platform

Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Oct 5, 2023

Primary completion

Sep 16, 2024

Study completion Sep 16, 2024

Sponsor

Lead sponsor
Eli Lilly and CompanyNot on our public-company list
Sponsor type
Industry
First posted
Jun 8, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.

Conditions

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Type 2 Diabetes Treated With Insulin

Interventions

  • Insulin LisproDrug

    As prescribed.

  • Tempo Smart ButtonDevice

    Attached to the Tempo Pen

  • Dexcom G6 CGMDevice

    Continuous glucose monitor

  • Glooko Research Mobile App (RMA)Device

    Installed on a study provided android phone.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Missed Bolus Doses (MBDs) Per WeekTime frame: Study Period 1: Week 6 ; Study Period 2: Week 18

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • CHU de Besancon Hopital Jean Minjoz

    Besançon, France

  • Centre Hospitalier Sud Francilien-Pharmacie

    Corbeil-Essonnes, France

  • Chu de Grenoble

    Grenoble Cédex 9, France

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.